Vivos Therapeutics launches restructuring plan targeting $3.6 million in annual savings starting Q4 2026
VVOS•Vivos Therapeutics launched a restructuring plan targeting $3.6 million in annual cost savings starting in Q4 2026, and aims to become cash-flow positive by late 2026 or early 2027.
1. Cost-saving measures
The plan includes staff cuts, vendor changes and renegotiated contracts, with additional reductions effective October 1, 2026. Management expects the full run-rate impact of the cuts to be reflected in the fourth quarter. Combined with revenue initiatives, the company targets cash-flow positive results by late 2026 or early 2027, while its profitability target remains 2027.
